Carlsmed Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	63.3	50.51	27.17	13.78
Revenue Growth	65.39%	85.94%	97.16%	-
Cost of Revenue	14.79	12.47	7.12	3.88
Gross Profit	48.5	38.04	20.05	9.9
Selling, General & Admin	66.24	51.6	29.87	21.1
Research & Development	20.93	17.02	14.3	7.4
Total Operating Expenses	87.17	68.61	44.17	28.49
Operating Income	-38.67	-30.57	-24.12	-18.59
Interest Income	3.71	2.7	1.33	0.33
Interest Expense	-1.33	-1.43	-1.32	-0.64
Other Non-Operating Income (Expense)	-0.06	-0.33	-0.14	-
Total Non-Operating Income (Expense)	2.32	0.94	-0.14	-0.31
Pretax Income	-36.35	-29.63	-24.26	-18.9
Net Income	-10.51	-29.63	-24.26	-18.9
Net Income Attributable to Preferred Dividends	-	0.58	0.59	-
Net Income to Common	-36.35	-30.22	-24.85	-18.9
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	25	14	4	4
Shares Outstanding (Diluted)	25	14	4	4
Shares Change	494.62%	249.74%	4.62%	-
EPS (Basic)	-1.43	-2.12	-6.11	-4.86
EPS (Diluted)	-1.43	-2.12	-6.11	-4.86
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-34.58	-29.62	-25.65	-17.62
Free Cash Flow Growth	-	-	-	-
Free Cash Flow Per Share	-1.36	-2.08	-6.31	-4.53
Gross Margin	76.63%	75.31%	73.80%	71.88%
Operating Margin	-61.09%	-60.53%	-88.80%	-134.93%
Profit Margin	-16.60%	-58.67%	-89.30%	-137.16%
FCF Margin	-54.63%	-58.64%	-94.41%	-127.85%
EBITDA	-38.26	-30.29	-23.98	-18.46
EBITDA Margin	-60.44%	-59.97%	-88.26%	-133.94%
EBIT	-38.67	-30.57	-24.12	-18.59
EBIT Margin	-61.09%	-60.53%	-88.80%	-134.93%

SEC Filings: 10-K · 10-Q